Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zhengye Biotechnology Holding EBITDA Margin % Related Terms
Zhengye Biotechnology Holding EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYBT vs TLPH, CPHI, CPIX: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhengye Biotechnology Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhengye Biotechnology Holding EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhengye Biotechnology Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zhengye Biotechnology Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhengye Biotechnology Holding (ZYBT) has a EBITDA Margin % of -47.43% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhengye Biotechnology Holding and its competitors. According to the industry distribution chart, Zhengye Biotechnology Holding ranks #835 out of 957 companies in the Drug Manufacturers industry, placing it in the top 87.3%.
Is Zhengye Biotechnology Holding's EBITDA Margin % too high?
Zhengye Biotechnology Holding's current EBITDA Margin % is -47.43%. Based on the distribution chart, Zhengye Biotechnology Holding ranks #835 out of 957 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's EBITDA Margin % compare to TLPH and CPHI?
According to the Drug Manufacturers industry distribution chart, Zhengye Biotechnology Holding ranks #835 out of 957 companies for EBITDA Margin %. This places Zhengye Biotechnology Holding in the lower half of its industry. The industry median EBITDA Margin % is 12.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.60, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhengye Biotechnology Holding and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhengye Biotechnology Holding's current EBITDA Margin % is -47.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current EBITDA Margin % of -47.43%. The current EBITDA Margin % is -47.43%. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current EBITDA Margin % is -47.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score
Get the complete analysis for ZYBT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYBT has been successfully added to your 
